Bellerophon Therapeutics (NASDAQ:BLPH) Coverage Initiated at StockNews.com

Research analysts at StockNews.com began coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research note issued on Monday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Trading Down 27.3 %

Shares of NASDAQ:BLPH opened at $0.04 on Monday. Bellerophon Therapeutics has a 12 month low of $0.03 and a 12 month high of $0.10. The stock has a market cap of $489,200.00, a P/E ratio of -0.05 and a beta of 0.71. The company has a 50 day moving average of $0.04 and a 200 day moving average of $0.05.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.